Oncology & Cancer

Multigene testing for all breast cancer patients cost-effective

(HealthDay)—Unselected, multigene testing for all patients with breast cancer would be cost-effective in the United Kingdom and the United States, according to a study published online Oct. 3 in JAMA Oncology.

Oncology & Cancer

Managing ovarian cancer risk in women with BRCA1/2 genetic variants

BRCA1 and BRCA2 genetic variants are a clinically important risk factor for the development of ovarian and breast cancer, and women who carry these variants have a lifetime risk of ovarian cancer of 39%-44% and 11%-17%, respectively.

Oncology & Cancer

New drug targets for BRCA-driven cancer uncovered

BRCA1 and BRCA2 ("BReast CAncer genes") are critical tumor suppressor genes—women carrying a mutation in one of these genes have up to an 80 percent risk of developing breast cancer and a 50 percent risk of developing ovarian ...

page 2 from 9